Selected Start-Ups (11/00)
In Vivo summarizes the technologies of several recently founded companies: CryoCor Inc.will use cryonic ablation technology to treat cardiac arrhythmias. Expert Biomed Inc.is engaged in the search for therapeutics for Alzheimer's disease as well as new cancer diagnostics. Hypnion Inc. will use specialized screening and functional genomics services to discover novel drugs for sleep disorders and circadian rhythm abnormalities. France's Nautilus Biotech will use its proprietary analytical and gene transfer vector technology to support the drug discovery efforts of its customers. Neurogenetics Inc. aims to develop small molecule therapeutics to halt the progression of Alzheimer's disease and other neurodegenerative disorders. Robinson Medical Inc. will commercialize technology for the non-invasive continuous, real-time measurement of blood flow during cardiac surgery.
You may also be interested in...
The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.